HAE

Companies
Nyse American
Haemonetics Corporation
Health Care
Price Chart
Overview

About HAE

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Market Cap
$4.4B
Volume
42.2M
Avg. Volume
57.1M
P/E Ratio
11.19101
Dividend Yield
0.00%
Employees
2.6K

Company Information

Exchange
Nyse American
Sector
Health Care
Industry
Medical Instruments & Supplies
Risk & Correlation Analysis
Market Correlation
0.74
Low Correlation
Volatility
Medium (0.36)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for HAE.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, HAE shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$4.4B
Volume42.2M
P/E Ratio11.19
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 7, 2025

PortfolioPilot Analysis

Get AI-powered insights on how HAE fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025